Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Given Consensus Rating of “Hold” by Analysts

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) has been assigned a consensus recommendation of “Hold” from the seventeen research firms that are currently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, twelve have given a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $21.25.

TNDM has been the subject of several recent analyst reports. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $24.00 price target on shares of Tandem Diabetes Care in a research report on Monday, September 29th. Stifel Nicolaus initiated coverage on shares of Tandem Diabetes Care in a research note on Tuesday, October 21st. They set a “hold” rating and a $15.00 price objective for the company. Citigroup reiterated a “neutral” rating and issued a $15.00 target price (up previously from $11.00) on shares of Tandem Diabetes Care in a research note on Tuesday, October 7th. Morgan Stanley increased their price target on shares of Tandem Diabetes Care from $13.00 to $17.00 and gave the company an “equal weight” rating in a report on Monday, November 10th. Finally, Wall Street Zen raised shares of Tandem Diabetes Care from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Acadian Asset Management LLC bought a new stake in shares of Tandem Diabetes Care in the first quarter worth $4,457,000. HighTower Advisors LLC lifted its holdings in Tandem Diabetes Care by 604.6% in the first quarter. HighTower Advisors LLC now owns 67,168 shares of the medical device company’s stock valued at $1,287,000 after acquiring an additional 57,635 shares during the period. Allianz Asset Management GmbH purchased a new position in Tandem Diabetes Care in the first quarter worth about $205,000. Edmond DE Rothschild Holding S.A. bought a new stake in shares of Tandem Diabetes Care during the 1st quarter valued at about $4,840,000. Finally, Voya Investment Management LLC increased its position in shares of Tandem Diabetes Care by 39.2% during the 1st quarter. Voya Investment Management LLC now owns 136,698 shares of the medical device company’s stock valued at $2,619,000 after purchasing an additional 38,519 shares during the last quarter.

Tandem Diabetes Care Stock Performance

Tandem Diabetes Care stock opened at $21.28 on Friday. Tandem Diabetes Care has a twelve month low of $9.98 and a twelve month high of $38.28. The company has a quick ratio of 1.90, a current ratio of 2.44 and a debt-to-equity ratio of 2.33. The company has a market capitalization of $1.44 billion, a P/E ratio of -6.98 and a beta of 1.51. The stock’s 50 day moving average is $14.87 and its 200 day moving average is $16.22.

Tandem Diabetes Care (NASDAQ:TNDM) last announced its quarterly earnings data on Thursday, November 6th. The medical device company reported ($0.31) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.31). Tandem Diabetes Care had a negative return on equity of 73.97% and a negative net margin of 20.19%.The business had revenue of $249.25 million during the quarter, compared to analysts’ expectations of $235.80 million. During the same quarter in the previous year, the business earned ($0.35) earnings per share. The firm’s quarterly revenue was up 2.2% compared to the same quarter last year. Tandem Diabetes Care has set its FY 2025 guidance at EPS. On average, equities research analysts predict that Tandem Diabetes Care will post -1.68 earnings per share for the current fiscal year.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.